Sharon Johnson appointed Executive Vice President for Delivery Management
Monday 10th February 2020
Vectura Group plc today announces a key appointment to support innovation, customer focus and growth as the company continues with its strategic development as a leading inhalation specialist in the pharmaceutical services space.
Sharon Johnson has been appointed to the position of Executive Vice President for Delivery Management, a newly-created leadership role focussed on helping the company to transform into a successful CDMO. In her new role, Ms. Johnson will build an end-to-end approach to ensuring successful customer acquisition and programme management, as well as managing the regulatory affairs and medical affairs departments. She joins the Group on 10th February.
Will Downie, CEO of Vectura, said: “Sharon has built an enviable reputation as an exceptional leader in the pharmaceutical services space and has a strong track record of transformational leadership, talent development and execution excellence. Our new structure will support growth and sharpen our focus on working with our clients to bring more inhaled medicines to market.”
Ms. Johnson added: “Having spent my entire career in the healthcare arena, it is a true privilege to join Vectura, a company with such a rich scientific heritage in the inhalation space. I look forward to working with my colleagues on the executive leadership team and wider business to help combine deep science and agile processes that will accelerate the development of new and exciting inhaled medicines for patients.”
Ms. Johnson has more than thirty years of experience in the pharmaceutical industry, and prior to joining Vectura has held a number of executive positions, most recently as Senior Vice President, Global Quality and Regulatory Affairs at Catalent, one of the world’s leading CDMOs. Earlier in her career, she held the position of Vice President of Quality for GE Healthcare’s Medical Diagnostic Division, and worked in roles of increasing responsibility for Baxter Healthcare and Sanofi Aventis.
Ms. Johnson holds a postgraduate Diploma in Industrial Pharmaceutical Studies with Distinction from Brighton University and a BS Honours degree in Biological Sciences/Microbiology from North East Surrey College of Technology.